ALX Oncology Holdings Inc.
ALXO
$1.93
-$0.08-3.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.24% | -0.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.66% | -17.61% | |||
| Operating Income | 3.66% | 17.61% | |||
| Income Before Tax | -0.25% | 21.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.25% | 21.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.25% | 21.54% | |||
| EBIT | 3.66% | 17.61% | |||
| EBITDA | 5.89% | 17.73% | |||
| EPS Basic | 22.70% | 59.28% | |||
| Normalized Basic EPS | 26.61% | 59.29% | |||
| EPS Diluted | 22.70% | 59.28% | |||
| Normalized Diluted EPS | 26.61% | 59.29% | |||
| Average Basic Shares Outstanding | 29.71% | 92.64% | |||
| Average Diluted Shares Outstanding | 29.71% | 92.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||